SD-RAVEN-INDUSTRIES,-INC
12.5.2021 15:17:07 CEST | Business Wire | Press release
Raven Industries, Inc. (the Company; NASDAQ:RAVN) a leader in agriculture technology, announced today the launch of its new product brand and autonomous growth platform, OMNi . This new product brand highlights Raven’s advancements in autonomous solutions for agriculture with a strategic offering of two integrated products: OMNiDRIVE™ and OMNiPOWER™ .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210512005126/en/
The OMNi name (meaning "all") will take center stage within Raven. “Empowering ‘all’ is exactly what OMNiPOWER™ and OMNiDRIVE™ bring to the agriculture industry. OMNi enables holistic, hands-free precision; it gives the farmer total control of their time and maximizes operational productivity and efficiency,” said Nick Langerock, Director of Strategic Marketing for Raven. “As we bring OMNi to market, we want farmers to understand that some of their pain points are now more manageable through autonomous solutions. OMNi solutions allow the farmer to trust the routine tasks to automation and focus on the important farm functions.”
Effective today, OMNiDRIVE™ replaces the AutoCart name from the previous acquisition of Smart Ag. The former DOT name is now OMNiPOWER™. All of Raven’s intelligent autonomous solutions for the agriculture industry will be branded with the OMNi prefix and are part of one connected ecosystem . This ecosystem leverages Raven’s innovative and ever-growing technology portfolio that makes smart products smarter. OMNi solutions provide multiple paths to autonomy and equip the ag professional to get more, do more, and give more from their operation.
“We understand the importance of quickly scaling and adopting new power platforms, farming applications, and implements into purpose-built autonomous agricultural machines,” said Dominic Walkes, Director of Strategic Initiatives at Raven. “OMNiDRIVE™ is a significant growth platform and we are actively working with OEM partners to release compatibility on additional tractors and implements. We are excited about the opportunities rolling out under the OMNi prefix as it ties our entire portfolio together and helps to provide the entire solution from top to bottom for the farmer.”
OMNiDRIVE™ is Raven’s aftermarket technology kit that transforms existing tractors into driverless machines. It is the first farming application that allows the farmer to monitor and operate a driverless tractor from the cab of the harvester so the harvester can offload on-the-go, then return the tractor and grain cart to a predetermined unloading area — all without a second driver.
The technology connects, manages, and safely operate autonomous agricultural machinery and is compatible with:
- Case IH Magnum CVT (2014-2020 models): M250 / 280 / 310 / 340 / 380 (available in October 2021)
- New Holland CVT (2014-2020 models): T8.320 / 350 / 380 / 410 / 435 (available in October 2021)
- John Deere 8Rs Powershift and IVT (2010-current models)
Over three dozen pre-orders have already been placed for OMNiDRIVE™. Official ordering begins today, May 12, 2021. Visit www.ravenprecision.com/omnidrive-offer to learn more about OMNiDRIVE introductory pricing.
OMNiPOWER™ is a self-propelled power platform that easily interchanges with farm implements. This will allow the ag professional to perform multiple farm tasks in all the growing seasons. The farmer launches missions in autonomous mode or can also control directly from the tablet. In either instance, no driver is necessary. Currently, OMNiPOWER™ has interchangeable implements for spreading and spraying with additional applications coming soon.
More OMNiPOWER™ implements will launch quickly and consistently as Raven works with OEM partners to release new implements. Visit www.ravenprecision.com/driverless-ag/partner-with-us to learn more.
OMNiPOWER™ will be available for order on June 1, 2021, with delivery in the fall of 2021.
“The future of agriculture is here and now,” said Langerock. “The pivot-point is OMNi. You'll see the new brand identity and campaign to reflect and communicate our advancements to the market.”
OMNiPOWER™ and OMNiDRIVE™ are trademarks of Raven Industries, Inc.
About Raven Industries, Inc.
Raven Industries (NASDAQ: RAVN) provides innovative, high-value products and systems that solve great challenges throughout the world. Raven is a leader in precision agriculture, high-performance specialty films, and aerospace and defense solutions, and the company’s groundbreaking work in autonomous systems is unlocking new possibilities in areas like farming, national defense, and scientific research. Since 1956, Raven has designed, produced, and delivered exceptional solutions, earning the company a reputation for innovation, product quality, and unmatched service. For more information, visit https://ravenind.com .
About Raven Applied Technology
For decades, Raven Applied Technology has been committed to maximizing operational efficiencies through its innovative agriculture technology. The company’s autonomous product suite is an extension of that core. From field computers to sprayer and planter controls, GPS guidance steering systems, logistics technology, and autonomous solutions — Raven provides precision agriculture products designed for ag retailers and growers to remain competitive and profitable into the future. Learn more at https://ravenprecision.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005126/en/
Link:
Social Media:
https://www.facebook.com/ravenprecision/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom